To characterize CH in CLL, 620 patients from two German CLL Study Group trials were analyzed (CLL12 (ibrutinib vs. placebo) and CLL14 (venetoclax-obinutuzumab [Ven-Obi] vs. chlorambucil-obinutuzumab [Clb-Obi])) using error-corrected next-generation sequencing with a VAF threshold of 0.5%. In contrast, CH had no prognostic impact in patients receiving targeted therapies. This study demonstrates the high prevalence of CH, highlights its differential impact across various CLL therapies and underscores its adverse influence on patient outcomes.

7 days ago

Journal

TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD34 (CD34 molecule) • BAX (BCL2-associated X protein) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)

Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)

11d

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)

P1, N=4, Active, not recruiting, AbbVie | Trial completion date: Jul 2029 --> Jul 2027 | Trial primary completion date: Jul 2029 --> Jul 2027

11 days ago

Trial completion date • Trial primary completion date • Adverse events

Gazyva (obinutuzumab) • surzetoclax (ABBV-453)

11d

Glofitamab Combined With CAR-T Therapy in R/R DLBCL (clinicaltrials.gov)

P2, N=24, Not yet recruiting, Ruijin Hospital

11 days ago

New P2 trial

TP53 (Tumor protein P53)

TP53 mutation

Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Carteyva (relmacabtagene autoleucel) • Columvi (glofitamab-gxbm)

11d

First-line treatment for CLL in the era of targeted therapy. (PubMed, Blood Cancer J)

The primary first-line treatment options for CLL comprise continuous therapies based on the BTK inhibitors ibrutinib, zanubrutinib, or acalabrutinib, or fixed-duration regimens combining the BCL2 inhibitor venetoclax with obinutuzumab or the BTK inhibitors ibrutinib or acalabrutinib (with or without obinutuzumab). Selecting the appropriate targeted therapy requires careful evaluation of a multitude of factors, including molecular disease features (especially del[17p]/TP53 and IGHV mutational status), comorbidities, comedications, and the patient's preferences. Focusing on primary treatment options, we review data from the key controlled trials that support the first-line use of targeted therapies for patients with CLL, consider ongoing trials that may support clinical decision-making in the future, and assess the potential to personalize treatment regimens in CLL based on minimal residual disease status.

11 days ago

Review • Journal • IO biomarker

TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)

TP53 mutation • IGH mutation

Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)

12d

Successful Zanubrutinib Monotherapy in a Rare CNS Presentation of Relapsed CLL. (PubMed, Case Rep Hematol)

We report a case of a 63-year-old male with a history of CLL previously treated with ibrutinib but discontinued early due to intolerance. As a result, the patient was then treated with obinutuzumab plus venetoclax, achieving undetectable minimal residual disease (MRD) but relapsed after 2 years with CNS involvement...He remains in complete remission with continued daily zanubrutinib 6 months follow-up; no significant adverse effects were observed. This case highlights the rare occurrence of CNS involvement in CLL and is the first to demonstrate successful CNS disease eradication with zanubrutinib monotherapy.

12 days ago

Journal

CD5 (CD5 Molecule)

Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)

12d

STARGLO: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)

P3, N=270, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2026 --> Mar 2028

12 days ago

Trial completion date • Trial primary completion date

gemcitabine • Rituxan (rituximab) • Gazyva (obinutuzumab) • oxaliplatin • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)

13d

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (clinicaltrials.gov)

P2, N=22, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting

13 days ago

Enrollment open

MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)

Chr del(11q)

clonoSEQ

Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)

13d

Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study (clinicaltrials.gov)

P2/3, N=20, Recruiting, Radboud University Medical Center | Not yet recruiting --> Recruiting

13 days ago

Enrollment open

Gazyva (obinutuzumab)

27d

ZGR in TN FL: Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma (clinicaltrials.gov)

P2, N=34, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

27 days ago

New P2 trial

lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)

30d

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)

P2, N=36, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027

30 days ago

Trial primary completion date

Gazyva (obinutuzumab) • golcadomide (CC-99282)

ZGR in SBLPN: Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial (clinicaltrials.gov)

P2, N=47, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial (clinicaltrials.gov)

P2, N=33, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Aug 2028 --> Jun 2029 | Trial primary completion date: Aug 2028 --> Jun 2029

1 month ago

Enrollment open • Trial completion date • Trial primary completion date

Venclexta (venetoclax) • Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)